Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cross Country Healthcare (CCRN) Shares Outstanding (Weighted Average) (2016 - 2025)

Cross Country Healthcare (CCRN) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $32.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) fell 3.57% year-over-year to $32.5 million, compared with a TTM value of $32.5 million through Sep 2025, down 3.57%, and an annual FY2024 reading of $33.4 million, down 5.06% over the prior year.
  • Shares Outstanding (Weighted Average) was $32.5 million for Q3 2025 at Cross Country Healthcare, roughly flat from $32.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $37.5 million in Q2 2022 and bottomed at $32.3 million in Q1 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $35.2 million, with a median of $35.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 2.93% in 2022, then dropped 5.79% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $36.7 million in 2021, then grew by 0.88% to $37.0 million in 2022, then fell by 5.01% to $35.2 million in 2023, then dropped by 5.06% to $33.4 million in 2024, then decreased by 2.56% to $32.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CCRN at $32.5 million in Q3 2025, $32.4 million in Q2 2025, and $32.3 million in Q1 2025.